INT195226

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.26
First Reported 2005
Last Reported 2010
Negated 0
Speculated 4
Reported most in Body
Documents 23
Total Number 28
Disease Relevance 7.85
Pain Relevance 12.62

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (ACR) DNA binding (ACR) protein complex (ACR)
Anatomy Link Frequency
T-cell 2
superior 1
arm 1
ACR (Homo sapiens)
Pain Link Frequency Relevance Heat
Adalimumab 1047 100.00 Very High Very High Very High
abatacept 429 99.98 Very High Very High Very High
methotrexate 553 99.64 Very High Very High Very High
Restless leg syndrome 240 99.48 Very High Very High Very High
Inflammation 174 98.80 Very High Very High Very High
Etanercept 166 98.44 Very High Very High Very High
diclofenac 9 95.12 Very High Very High Very High
rheumatoid arthritis 872 92.44 High High
aspirin 44 90.16 High High
cytokine 84 74.80 Quite High
Disease Link Frequency Relevance Heat
Disease 394 99.84 Very High Very High Very High
Increased Venous Pressure Under Development 260 99.48 Very High Very High Very High
INFLAMMATION 226 98.80 Very High Very High Very High
Rheumatoid Arthritis 884 92.44 High High
Toxicity 13 91.32 High High
Infection 183 88.48 High High
Cv Unclassified Under Development 18 84.76 Quite High
Edema 8 83.84 Quite High
Myalgia 4 65.44 Quite High
Proteinuria 10 61.04 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Additionally, those patients receiving 4 mg/kg or 8 mg/kg of tocilizumab in combination with MTX also achieved an ACR50 and ACR70 response that was significantly increased in comparison with MTX alone.
Positive_regulation (increased) of ACR50 associated with methotrexate
1) Confidence 0.26 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.07 Pain Relevance 0.36
Additionally, those patients receiving 4 mg/kg or 8 mg/kg of tocilizumab in combination with MTX also achieved an ACR50 and ACR70 response that was significantly increased in comparison with MTX alone.
Positive_regulation (increased) of ACR70 associated with methotrexate
2) Confidence 0.26 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.07 Pain Relevance 0.36
In the combination groups, an ACR20 response was achieved by a statistically significantly greater number of patients compared with MTX plus placebo.
Positive_regulation (response) of ACR20 associated with methotrexate
3) Confidence 0.25 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.08 Pain Relevance 0.36
These changes correlated with a higher ACR response in both the tocilizumab and DMARD cohorts.
Positive_regulation (response) of ACR
4) Confidence 0.25 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.13 Pain Relevance 0.10
Overall, the increases in adalimumab ACR20, ACR50, and ACR70 response rates were time dependent (Fig. 2).
Positive_regulation (increases) of ACR20 associated with adalimumab
5) Confidence 0.16 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2668560 Disease Relevance 0.12 Pain Relevance 0.35
Overall, the increases in adalimumab ACR20, ACR50, and ACR70 response rates were time dependent (Fig. 2).
Positive_regulation (increases) of ACR50 associated with adalimumab
6) Confidence 0.16 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2668560 Disease Relevance 0.12 Pain Relevance 0.35
At Week 24, adalimumab demonstrated dose-dependent increases in ACR20 response rates and all adalimumab treatment groups achieved statistically significantly higher ACR20 responses (28.7% in the 20 mg group, P < 0.05; 44.0% in the 40 mg group, P < 0.001; and 50.6% in the 80 mg group, P < 0.001) compared with the placebo group (13.8%) (Table 2).


Positive_regulation (increases) of ACR20 associated with adalimumab
7) Confidence 0.14 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2668560 Disease Relevance 0.35 Pain Relevance 0.39
The increases in ACR have been shown to be attenuated by exercise therapy [9].
Positive_regulation (increases) of ACR
8) Confidence 0.12 Published 2006 Journal Thromb J Section Body Doc Link PMC1540420 Disease Relevance 0.82 Pain Relevance 0.49
This finding is in contrast to the more pronounced effect in patients who were RF/anti-CCP seropositive observed in a previous study.11 However, the superior response of patients who were seropositive strengthened over time, as shown by greater decreases in disease activity and enhanced ACR responses at week 48 in rituximab-treated patients who were seropositive compared with patients who were seronegative.
Positive_regulation (enhanced) of ACR in superior associated with disease
9) Confidence 0.11 Published 2010 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2938895 Disease Relevance 0.25 Pain Relevance 0.10
In addition, the last observation carried forward post baseline was conducted for the following analyses: ACR20 response rate at Week 24; ACR50 and ACR70 at Weeks 12 and 24; ACR20 at Week 12; individual components of the ACR response at Weeks 0 (predose), 12, and 24; and ACR20 AUC.
Spec (analyses) Positive_regulation (conducted) of ACR20
10) Confidence 0.10 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2668560 Disease Relevance 0 Pain Relevance 0.10
ACR50 and ACR70 responses were statistically significantly greater in all adalimumab treatment groups compared with placebo at Weeks 12 and 24, except for the ACR50 response for the 20 mg group at Week 24 and the ACR70 response for the 20 mg group at Week 12 (Table 2).
Positive_regulation (response) of ACR70 associated with adalimumab
11) Confidence 0.10 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2668560 Disease Relevance 0.13 Pain Relevance 0.35
Overall, the increases in adalimumab ACR20, ACR50, and ACR70 response rates were time dependent (Fig. 2).
Positive_regulation (increases) of ACR70 associated with adalimumab
12) Confidence 0.10 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2668560 Disease Relevance 0.12 Pain Relevance 0.35
In addition, the last observation carried forward post baseline was conducted for the following analyses: ACR20 response rate at Week 24; ACR50 and ACR70 at Weeks 12 and 24; ACR20 at Week 12; individual components of the ACR response at Weeks 0 (predose), 12, and 24; and ACR20 AUC.
Spec (analyses) Positive_regulation (conducted) of ACR50
13) Confidence 0.10 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2668560 Disease Relevance 0 Pain Relevance 0.10
In addition, the last observation carried forward post baseline was conducted for the following analyses: ACR20 response rate at Week 24; ACR50 and ACR70 at Weeks 12 and 24; ACR20 at Week 12; individual components of the ACR response at Weeks 0 (predose), 12, and 24; and ACR20 AUC.
Spec (analyses) Positive_regulation (conducted) of ACR20
14) Confidence 0.10 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2668560 Disease Relevance 0 Pain Relevance 0.10
The clinical significance of this increase in ACR is unclear but it has been shown to be attenuated following exercise training [9].
Positive_regulation (increase) of ACR
15) Confidence 0.08 Published 2006 Journal Thromb J Section Body Doc Link PMC1540420 Disease Relevance 0.97 Pain Relevance 0.87
The ACR, increased only in the patient with IC immediately following treadmill exercise and returned to baseline levels at 1 hour.
Positive_regulation (increased) of ACR associated with restless leg syndrome
16) Confidence 0.08 Published 2006 Journal Thromb J Section Body Doc Link PMC1540420 Disease Relevance 0.98 Pain Relevance 0.87
There was a significant increase in ACR following exercise in patients with IC only (p= 0.025) which returned to baseline values at 1 hour (table 3).


Positive_regulation (increase) of ACR associated with restless leg syndrome
17) Confidence 0.08 Published 2006 Journal Thromb J Section Body Doc Link PMC1540420 Disease Relevance 0.98 Pain Relevance 0.94
The three primary outcome measurements were the percentage of patients with an ACR20 response after 6 months, the percentage of patients with a significant improvement (?
Positive_regulation (response) of ACR20
18) Confidence 0.05 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012435 Disease Relevance 0.23 Pain Relevance 0.66
Of the patients with ACR20 after 6 months, 42.9% of those receiving abatacept achieved ACR50 after 1 year compared with 14.3% of placebo recipients, and 21% versus 2% improved to ACR70 (Dougados et al. 2007b).
Positive_regulation (achieved) of ACR50 associated with abatacept
19) Confidence 0.05 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012435 Disease Relevance 0.25 Pain Relevance 0.73
Compared with patients who received methotrexate, patients taking the 25 mg dose of etanercept exhibited a more rapid rate of improvement, with significantly more patients having ACR20, ACR50, and ACR70 response improvement in disease activity during the first 6 months (P < 0.05).
Positive_regulation (improvement) of ACR20 associated with disease, etanercept and methotrexate
20) Confidence 0.05 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC2833970 Disease Relevance 0.39 Pain Relevance 0.79

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox